US20110229871A1

US20110229871A1 - Nucleoside-containing compositions and methods for treating red blood cells

Info

Publication number: US20110229871A1
Application number: US13/028,819
Authority: US
Inventors: Daniel G. Ericson
Original assignee: Viacell LLC
Current assignee: Viacell LLC
Priority date: 2010-02-16
Filing date: 2011-02-16
Publication date: 2011-09-22
Also published as: US10537097B2; US20170251660A1; WO2011103177A1

Abstract

Blood storage and/or rejuvenating compositions that include D-ribose and a nucleoside other than inosine (e.g., guanosine) are disclosed herein. Such compositions can be useful in methods for treating (e.g., storing and/or rejuvenating) red blood cells.

Description

This application claims the benefit of U.S. Provisional Application No. 61/338,299, filed Feb. 16, 2010, which is incorporated herein by reference in its entirety.

BACKGROUND

Whole blood is a living tissue that circulates through the heart, arteries, veins and capillaries, carrying nourishment, electrolytes, antibodies, heat and oxygen to the body tissues. Whole blood includes red blood cells (RBCs), white blood cells and platelets suspended in a proteinaceous fluid termed blood plasma. If blood is treated to prevent clotting and permitted to stand in a container, RBCs will settle to the bottom of the container, the plasma will remain on top and the white blood cells will foam a layer on top of the RBCs. A centrifuge is commonly used to hasten this separation. The platelet-rich plasma is then removed and placed into a sterile bag for further processing to separate, for example, platelets, clotting factors, albumin, immunoglobulins and the like.
The most important component for the usual transfusion need are the erythrocytes or RBCs, which contain hemoglobin, a complex iron-containing protein that carries oxygen throughout the body and gives blood its red color. The percentage of blood volume that is composed of RBCs is called the “hematocrit.” The average hematocrit in the adult male is 47%. There are about one billion RBCs in two or three drops of blood, and, for every 600 RBCs, there are about 40 platelets and one white blood cell.
Manufactured in the bone marrow, RBCs are enucleated, biconcave discs that are continuously being produced, broken down and destroyed. The biconcave disc shape is crucial to the function of RBCs, presenting a maximal surface area for the capture of oxygen in the lungs and its release in the tissue. The cells are flexible and able to bend in order to traverse the tiny tubules of the capillary beds. Since the cells are enucleated and lack mitochondria, they are unable to carry out cellular repair processes and must rely on anaerobic phosphorylation for energy. After an average of 120 days in the circulatory system, the cells are senescent and are phagocytized by circulating monocytes or the fixed macrophages of the reticulo-endothelial system.
RBCs are prepared from whole blood by removing the plasma. When transfused into a patient, the hematocrit is raised while an increase in blood volume is minimized, which is especially important to such patients as those with congestive heart failure. The cells are typically suspended in about half the original volume; the preparation is referred to as packed red cells. Patients benefiting most from transfusions of RBCs include those with chronic refractive anemia from disorders such as kidney failure, malignancies, gastrointestinal bleeding or acute blood loss as from trauma or surgery.
Because patients seldom require all of the components of whole blood; it is the usual practice in blood banks to separate the blood into components and transfuse only that portion needed by the patient for a specific condition or disease. This treatment, referred to as “blood component therapy” allows several patients to benefit from each unit of blood. Unfortunately, the separation of blood components for therapy is detrimental to the RBCs, causing a storage lesion characterized by a decrease in the marker 2,3-diphosphoglycerate (2,3-DPG), an increase in the production of oxygen free radicals and a change in morphology.
Standard solutions for the storage of whole blood include citrate-phosphate-dextrose solution (CPD) and citrate-phosphate-dextrose-adenine solution (CPDA). Citrate or other anticoagulants such as heparin are necessary to prevent clotting. Because blood is a living tissue that maintains metabolic functions even at refrigerated temperatures, it has been considered necessary to provide an energy source such as dextrose. Phosphate ion can be used to buffer the lactate produced from dextrose utilization.
Improvements in cell preservation solutions over the last 15 years have increased the refrigerated shelf life of whole blood or RBCs from 21 to 42 days. After 42 days, the blood is discarded, since many of the cells have become senescent and would be immediately phagocytized upon transfusion into a recipient. Although the red cells may appear to survive in storage for five or six weeks, they rapidly develop storage lesions characterized by hemolysis and/or biochemical and biomechanical changes that can compromise their survival time and their ability to accept, transport, and unload oxygen to the tissue. For that reason, it is desirable to use the whole blood and blood products within three weeks or less of drawing.
The need remains for a solution in which blood cells in whole blood or packed red cell suspensions can be stored for an increased time and survive functionally when transfused into a recipient. The need also remains for a method to rejuvenate blood and RBCs which are functioning sub-optimally.

SUMMARY

Methods of collecting and storing RBCs prior to transfusion continue to be a challenge in improving blood bank practice. RBCs can be stored for 42 days at 4° C., but over this time RBC storage lesions occur despite improvements of anticoagulant solutions and blood additives. Among the most significant storage lesions of RBCs are a) the depletion of 2,3-DPG, resulting in a decrease in the ability of the blood to offload oxygen to tissue leading to an increase in oxygen affinity; b) morphological changes that reduce cell viability, increase fragility, and decrease deformability, impacting the ability of the cell to traverse the microcirculation; and c) the release of biochemical substances that result in fever, cellular damage, and tissue dysfunction. These storage lesions predominantly result from the depletion of cellular energy (i.e., adenosine triphosphate, or ATP) and lactic acid accumulation associated with decreased energy metabolism.
Experimental additive solutions that slow the rate of 2,3-DPG depletion and ATP loss are known. See, for example, Dawson et al., Prog Clin Biol Res. 1985; 195:349-68; Dawson et al., Transfusion 1984 July-August; 24(4):327-9; Dawson et al., Hum Pathol. 1983 March; 14(3):213-7; Dawson et al., Transfusion 1981 May-June; 21(3):285-90; and Dawson et al., Transfusion 1981 March-April; 21(2):215. These experimental solutions typically include a series of inorganic phosphates and inosine. Although the solutions are capable of maintaining 2,3-DPG levels to some degree, the requirement of the solution constituents created some issues that limited their utility. One issue was the low solubility of inosine, which resulted in a slurry being added to the RBCs that would subsequently require washing the cells prior to transfusion. Another issue is the biochemical progression leading to the formation of the potentially toxic breakdown products such as hypoxanthine and uric acid. Furthermore, the transfusion product must be warmed for one hour prior to transfusion, which impacts the practicality of such an additive solution in current blood banking practice. In preferred embodiments, the blood storage and/or rejuvenating compositions disclosed herein address one or more of these issues.
In one aspect, the present disclosure provides a blood storage and/or rejuvenating composition. In one embodiment, the composition includes a nucleoside and D-ribose, with the proviso that the nucleoside is not inosine. In certain embodiments, the nucleoside includes one or more of adenosine, deoxyadenosine, guanosine, deoxyguanosine, 5′-methyluridine, thymidine, uridine, deoxyuridine, cytidine, and deoxycytidine. In preferred embodiments, the nucleoside is guanosine. Optionally, the composition can further include sodium pyruvate and/or inorganic phosphate. In certain embodiments the composition is an aqueous solution.
In another embodiment, the blood storage and/or rejuvenating composition includes 75 to 1500 mM guanosine. Optionally, the composition can further include D-ribose at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include sodium pyruvate at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include an inorganic phosphate at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include L-arginine at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include inosine at a concentration of, for example, 75 to 1500 mM. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 2.5 to 50 mM guanosine; and optionally 2.5 to 50 mM D-ribose, 2.5 to 50 mM sodium pyruvate, 2.5 to 50 mM inorganic phosphate, 2.5 to 50 mM L-arginine, and/or 2.5 to 50 mM inosine.
In certain preferred embodiments, the blood storage and/or rejuvenating composition includes 150 to 900 mM guanosine. Optionally, the composition can further include D-ribose at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include sodium pyruvate at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include an inorganic phosphate at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include L-arginine at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include inosine at a concentration of, for example, 150 to 900 mM. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 5 to 30 mM guanosine; and optionally 5 to 30 mM D-ribose, 5 to 30 mM sodium pyruvate, 5 to 30 mM inorganic phosphate, 5 to 30 mM L-arginine, and/or 5 to 30 mM inosine.
In other preferred embodiments, the blood storage and/or rejuvenating composition includes 300 to 600 mM guanosine. Optionally, the composition can further include D-ribose at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include sodium pyruvate at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include an inorganic phosphate at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include L-arginine at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include inosine at a concentration of, for example, 300 to 600 mM. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 10 to 20 mM guanosine; and optionally 10 to 20 mM D-ribose, 10 to 20 mM sodium pyruvate, 10 to 20 mM inorganic phosphate, 10 to 20 mM L-arginine, and/or 10 to 20 mM inosine.
In another embodiment, the blood storage and/or rejuvenating composition includes: 225 mM guanosine; 300 mM D-ribose; 300 mM sodium pyruvate; and 300 mM inorganic phosphate. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 7.5 mM guanosine, 10 mM D-ribose, 10 mM sodium pyruvate, and 10 mM inorganic phosphate.
The compositions described herein can be used, for example, in a method of storing blood. In certain embodiments, the method includes contacting RBCs with a blood storage and/or rejuvenating composition as described herein.
Alternatively, or in addition to, the compositions described herein can be used, for example, in a method of rejuvenating blood. In certain embodiments, the method includes contacting RBCs with a blood storage and/or rejuvenating composition as described herein.
Methods for storing and/or rejuvenating RBCs are described herein. Additional methods are described, for example, in U.S. Patent Application Publication No. 2007/0111191 A1 (St. Cyr et al.), U.S. Pat. No. 7,687,468 (St. Cyr et al.), and copending U.S. patent application Ser. No. ______, entitled “ARGININE-CONTAINING COMPOSITIONS AND METHODS FOR TREATING RED BLOOD CELLS” (Attorney Docket No. 374.00020101), filed the same day herewith.
The technology described within this application describes a RBC storage and/or rejuvenating composition that, in preferred embodiments, does not present the solubility difficulties associated with inosine, does not produce a high level of breakdown products, and/or does not require warming of the RBCs prior to transfusion. The storage and/or rejuvenating composition described herein includes a pentose carbohydrate (e.g., D-Ribose) that can serve to aid de novo synthesis and metabolic salvage of purine nucleotides including ATP. The storage and/or rejuvenating composition can also include inorganic phosphate, which can serve as a substrate for phosphorolysis; and/or sodium pyruvate, which can serve as a source for NAD and allow 1,3-diphosphoglycerate to be converted to either 2,3-DPG or 3-phosphoglycerate. In one embodiment, guanosine can be used in place of inosine, which effectively can reduce the breakdown products produced by inosine, and can further enhance RBC ATP content. In another embodiment, L-arginine can be utilized to fully solubilize any inosine present.

DEFINITIONS

Unless otherwise specified, “a,” “an,” “the,” and “at least one” are used interchangeably and mean one or more than one.
As used herein, the term “comprising,” which is synonymous with “including” or “containing,” is inclusive, open-ended, and does not exclude additional unrecited elements or method steps.
Also herein, the recitations of numerical ranges by endpoints include all numbers subsumed within that range (e.g., 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).
The above brief description of various embodiments of the present invention is not intended to describe each embodiment or every implementation of the present invention. Rather, a more complete understanding of the invention will become apparent and appreciated by reference to the following description and claims. Further, it is to be understood that other embodiments may be utilized and structural changes may be made without departing from the scope of the present invention.

DETAILED DESCRIPTION OF ILLUSTRATIVE EMBODIMENTS

In 1915, blood transfusion was first attempted from a direct donor to a recipient. During the years following World War I, the practice improved with the use of a citrate glucose solution to collect the blood, the use of refrigeration, and blood typing. Then, in the 1960's and 1970's, improvements continued when glass bottle storage was replaced with durable plastic bags, better anticoagulants were developed, and the addition of mannitol and adenine allowed for storage of RBCs for 42 days. See, for example, Bartlett et al., J. Clin. Invest. 1960; 39:56; Bunn et al., J. Clin. Invest. 1969; 48:311; Akerblom et al., Scand. J. Clin. Lab. Invest. 1968; 21:245-248; and Delivoria-Papadopoulos et al., Science 1969; 165:601-602. Today, blood is still preserved with various anticoagulant solutions that include adenine and citrate. The blood is stored at 4° C., collected in plasticized blood bags, and discarded if not used within 42 days because over this six week storage period RBC viability is largely lost. As RBCs die, the lysed cells release the more durable hemoglobin molecule, which has a low P50, and which presents a barrier to oxygen diffusion.
Today some estimate that there are approximately 16 million units of RBCs transfused annually in the United States. This number constitutes an average of 34,000 units used every day to support patients undergoing surgery (especially heart, liver, and kidney), cancer treatment, complications of sickle cell anemia, trauma, sepsis, and various conditions requiring critical care. Although several complications have been associated with RBC transfusion, the overall transfusion rate among patients in intensive care is reported to be 44% (Corwin et al., Crit. Care Med., 2004; 32:39-52). Certain of the reported complications result from inherent properties of the blood products transfused, while others are a consequence of RBC storage.
RBCs undergo major biochemical and biomechanical changes during storage that affect their post transfusion performance and recent studies have drawn attention to possible adverse effects from older stored blood. See, for example, Walsh et al., Crit. Care Med. 2004; 32:364-371; Van de Watering et al., Transfusion 2006; 46:1712-1718; Vamvakas et al., Transfusion 2000; 40:101-109; and Hebert et al., Anesthesia & Analgesia. 2005; 100:1433-1438. The RBC storage lesion is evidenced by the loss of 2,3-DPG, the principal organic phosphate of the human erythrocyte. The 2,3-DPG content within the cell correlates with the position of the oxygen-hemoglobin dissociation curve, as reflected by the P50 (the partial pressure of oxygen at which hemoglobin is 50% saturated) in a variety of clinical conditions, including hypoxic states such as exposure to high altitude and cyanotic heart disease; a variety of anemia's; hyperthyroidism; septic shock; and the changes associated with blood storage (Oski et al., Blood 1971; 37:52-58). In blood stored under conventional blood bank conditions, the 2,3-DPG level drops sharply, and by 10 days of storage 2,3-DPG levels are only 20-25 percent of their original level. Within 21 days of storage they fall to 10 percent of their initial content (Van de Watering et al., Transfusion 2006; 46:1712-1718; and Vamvakas et al., Transfusion 2000; 40:101-109.
Storage lesions remain a significant concern and a major focus of research in transfusion medicine. Research evidence suggests that storage of RBCs for long periods of time results in reduced oxygen delivery, and transfusion of older blood (i.e., greater than 14-days of storage) has been identified as an independent risk factor for the development of multiple organ failure. See, for example, (Fitzgerald et al., Crit. Care Med. 1997; 25:726-732; Marik et al., JAMA, 1993; 269:3024-3029; Raat et al., Crit. Care Med., 2005; 33:39-45; and Zallen et al., Am. J. Surg., 1999; 178:570-572).
Based on the results of early studies (e.g., Van de Watering et al., Transfusion 2006; 46:1712-1718; and Vamvakas et al., Transfusion 2000; 40:101-109), it has been assumed that 2,3-DPG levels in RBCs are rejuvenated within 24-hours of transfusion. These studies were performed in normal volunteers with no circulatory problems and with normal blood volume. It is not known whether such recovery would occur in patients suffering from severe blood loss, circulatory issues, or problems associated with underlying medical conditions. Further, the inability of transfused RBCs to deliver oxygen to tissue during the critical time in the early hours following transfusion may have a significant impact on clinical outcome. Although certain studies indicate that the age of transfused RBCs has little or no effect on clinical outcomes in certain conditions (e.g., Hebert et al., Anesthesia & Analgesia. 2005; 100:1433-1438), others suggest the opposite, showing that the duration of storage of RBCs is associated with adverse outcome (Oski et al., Blood 1971; 37:52-58).
A predominance of the literature suggests the development of an RBC storage solution(s) that would limit or reverse storage lesions would be of considerable consequence to transfusion medicine and could help make RBC transfusion safer and more effective. See, for example, Fitzgerald et al., Crit. Care Med. 1997; 25:726-732; Marik et al., JAMA, 1993; 269:3024-3029; Raat et al., Crit. Care Med., 2005; 33:39-45; Zallen et al., Am. J. Surg., 1999; 178:570-572; Buetler et al., J. Lab. CLin. Med., 1969; 74:300; and Valerie et al., J. Lab. Clim. Med., 1969; 73:722-733. It is postulated that presently disclosed RBC storage and/or rejuvenating compositions will provide such a restorative benefit.
In one aspect, the present disclosure provides a blood storage and/or rejuvenating composition. In one embodiment, the composition includes a nucleoside and D-ribose, with the proviso that the nucleoside is not inosine. In certain embodiments, the nucleoside includes one or more of adenosine, deoxyadenosine, guanosine, deoxyguanosine, 5′-methyluridine, thymidine, uridine, deoxyuridine, cytidine, and deoxycytidine. In preferred embodiments, the nucleoside is guanosine. Optionally, the composition can further include sodium pyruvate and/or inorganic phosphate. In certain embodiments the composition is an aqueous solution. In preferred embodiments, the composition is an aqueous composition having a pH of 6 to 8.5.
In another embodiment, the blood storage and/or rejuvenating composition includes 75 to 1500 mM guanosine. Optionally, the composition can further include D-ribose at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include sodium pyruvate at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include an inorganic phosphate at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include L-arginine at a concentration of, for example, 75 to 1500 mM. Optionally, the composition can further include inosine at a concentration of, for example, 75 to 1500 mM. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 2.5 to 50 mM guanosine; and optionally 2.5 to 50 mM D-ribose, 2.5 to 50 mM sodium pyruvate, 2.5 to 50 mM inorganic phosphate, 2.5 to 50 mM L-arginine, and/or 2.5 to 50 mM inosine.
In certain preferred embodiments, the blood storage and/or rejuvenating composition includes 150 to 900 mM guanosine. Optionally, the composition can further include D-ribose at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include sodium pyruvate at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include an inorganic phosphate at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include L-arginine at a concentration of, for example, 150 to 900 mM. Optionally, the composition can further include inosine at a concentration of, for example, 150 to 900 mM. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 5 to 30 mM guanosine; and optionally 5 to 30 mM D-ribose, 5 to 30 mM sodium pyruvate, 5 to 30 mM inorganic phosphate, 5 to 30 mM L-arginine, and/or 5 to 30 mM inosine.
In other preferred embodiments, the blood storage and/or rejuvenating composition includes 300 to 600 mM guanosine. Optionally, the composition can further include D-ribose at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include sodium pyruvate at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include an inorganic phosphate at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include L-arginine at a concentration of, for example, 300 to 600 mM. Optionally, the composition can further include inosine at a concentration of, for example, 300 to 600 mM. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 10 to 20 mM guanosine; and optionally 10 to 20 mM D-ribose, 10 to 20 mM sodium pyruvate, 10 to 20 mM inorganic phosphate, 10 to 20 mM L-arginine, and/or 10 to 20 mM inosine.
In another embodiment, the blood storage and/or rejuvenating composition includes: 225 mM guanosine; 300 mM D-ribose; 300 mM sodium pyruvate; and 300 mM inorganic phosphate. When used to store and/or rejuvenate blood, the composition is typically diluted approximately 30-fold to provide a final concentration of 7.5 mM guanosine, 10 mM D-ribose, 10 mM sodium pyruvate, and 10 mM inorganic phosphate.
The compositions described herein can be used, for example, in a method of storing blood. In certain embodiments, the method includes contacting RBCs with a blood storage and/or rejuvenating composition as described herein.
Alternatively, or in addition to, the compositions described herein can be used, for example, in a method of rejuvenating blood. In certain embodiments, the method includes contacting RBCs with a blood storage and/or rejuvenating composition as described herein.
In certain preferred embodiments, the method of rejuvenating blood includes: providing RBCs (e.g., packed RBCs or in whole blood) having a 2,3-DPG value lower than the value for freshly drawn blood; and mixing the RBCs with a blood storage and/or rejuvenating composition under conditions effective to increase the 2,3-DPG value, wherein the blood storage and/or rejuvenating composition includes guanosine. In certain embodiments, conditions effective to increase the 2,3-DPG value include incubating the cells in the blood storage and/or rejuvenating composition at a temperature of 4° C. to 37° C., and in certain preferred embodiments at a temperature of room temperature. In certain embodiments, conditions effective to increase the 2,3-DPG value include incubating the cells in the blood storage and/or rejuvenating composition for a time of at least 10 minutes, in preferred embodiments for a time of 10 minutes to 48 hours, in certain preferred embodiments for a time of 10 minutes to 4 hours, and in other preferred embodiments for a time of 30 minutes to 2 hours. Exemplary conditions effective to increase the 2,3-DPG value include incubating the cells in the blood storage and/or rejuvenating composition at 37° C. for 10 minutes to four hours. Other exemplary conditions effective to increase the 2,3-DPG value include incubating the cells in the blood storage and/or rejuvenating composition at room temperature for 10 minutes to four hours. In preferred embodiments, the blood storage and/or rejuvenating composition includes one or more of the blood storage and/or rejuvenating compositions described herein.
In certain preferred embodiments, the method of rejuvenating blood includes: providing RBCs (e.g., packed RBCs or in whole blood) having an ATP value lower than the value for freshly drawn blood; and mixing the RBCs with a blood storage and/or rejuvenating composition under conditions effective to increase the ATP value, wherein the blood storage and/or rejuvenating composition includes guanosine. In certain embodiments, conditions effective to increase the ATP value include incubating the cells in the blood storage and/or rejuvenating composition at a temperature of 4° C. to 37° C., and in certain preferred embodiments at a temperature of room temperature. In certain embodiments, conditions effective to increase the ATP value include incubating the cells in the blood storage and/or rejuvenating composition for a time of at least 10 minutes, in preferred embodiments for a time of 10 minutes to 48 hours, in certain preferred embodiments for a time of 10 minutes to 4 hours, and in other preferred embodiments for a time of 30 minutes to 2 hours. Exemplary conditions effective to increase the ATP value include incubating the cells in the blood storage and/or rejuvenating composition at 37° C. for 10 minutes to four hours. Other exemplary conditions effective to increase the ATP value include incubating the cells in the blood storage and/or rejuvenating composition at room temperature for 10 minutes to four hours. In preferred embodiments, the blood storage and/or rejuvenating composition includes one or more of the blood storage and/or rejuvenating compositions described herein.
By increasing 2,3-DPG concentration in stressed RBCs, it is postulated RBC storage and/or rejuvenating compositions as disclosed herein will decrease oxygen affinity and increase oxygen delivery to affected tissue following transfusion. Further, by maintaining cellular energetics, it is hypothesized that the storage and/or rejuvenating compositions disclosed herein will decrease cell fragility and increase deformability, thereby improving flow through the capillaries. The net result will be a decrease in storage lesions and greater oxygen delivery to affected tissue following transfusion.
The present invention is illustrated by the following examples. It is to be understood that the particular examples, materials, amounts, and procedures are to be interpreted broadly in accordance with the scope and spirit of the invention as set forth herein.

EXAMPLES

Example 1

A storage and/or rejuvenating composition that includes D-ribose, inosine, sodium pyruvate, and inorganic phosphate, all at a 300 mM concentration as a slurry was prepared. When used to store and/or rejuvenate RBCs, the slurry is diluted 30-fold to a final concentration of 10 mM to form a solution. The composition exhibits significant results in restoring 2,3-DPG levels in stored RBCs and increasing the ATP content from the baseline value. In a study, RBCs were collected and stored for an average of 21 days at 4° C. according to standard blood banking practice. Various RBC storage and/or rejuvenating compositions were added to the 21-day old stored RBCs and held at 37° C. for one to four hours before being tested for 2,3-DPG concentrations. 2,3-DPG levels were measured in all the examples using a diagnostic 2,3-diphosphoglycerate (DPG) kit available from Roche Diagnostics Corp. (Cat. #10148334001). A normal 2,3-DPG concentration of RBC immediately upon harvest is 4.0 μmol/ml. Following storage the average 2,3-DPG concentration fell to 0.17 μmol/ml (Table 1). The addition of RBC storage and/or rejuvenating composition restored the concentration to greater than 50% of normal post-harvest level. An increase to 1.0 μmol/ml is considered a significant improvement. This series of experiments demonstrated a RBC storage and/or rejuvenating composition increased ATP content and 2,3-DPG levels. The practicality of the solution for adoption in blood bank practice may be limited, however, due to the low solubility of inosine as well as the need for warming of the blood (e.g., for one hour) prior to transfusion.

TABLE 1

2,3-DPG Level of Stored RBCs with RBC Storage and/or Rejuvenating
Composition

	Average 2,3-
Time Point	DPG	Range		% ATP
(Hours)	(μmol/ml)	(μmol/ml)	N =	increase

0	0.17	0.07-0.35	5
1	2.4	1.8-3.3	10	24
2	1.8	1.2-2.7	10	22

Experimental protocols were designed to find methods to increase the solubility of inosine. It was found that L-arginine in an equimolecular solution enhanced the inosine solubility such that inosine remained in solution at concentrations above 50 mM at room temperature. A storage and/or rejuvenating composition including 300 mM each of inosine, L-arginine, sodium pyruvate, D-ribose, and inorganic phosphate was diluted 30-fold into 21-day old stored RBCs. One set of stored blood samples was incubated for 60 minutes at room temperature and another was incubated for 60 minutes at 37° C. As shown in Table 2, the L-arginine containing storage and/or rejuvenating compositions successfully restored 2,3-DPG and ATP levels regardless of mode of warming. This result demonstrates the rejuvenation of 2,3-DPG and ATP using room temperature incubation and a solution devoid of problems associated with slurries and washing of the red cells prior to transfusion.

TABLE 2

2,3-DPG and ATP of stored RBC in L-arginine containing solution

	Average 2,3-	Range
	DPG	(μmol/		% ATP
Sample	(μmol/ml)	ml)	N =	increase

Control	0.29	N.A.	1
60 minutes at	3.2	2.9-3.5	3	29
37° C.
60 minutes at	1.3	1.0-1.5	3	27
Room
Temperature

Example 2

An additional experimental protocol was designed to determine if nucleosides other than inosine can successfully aid in restoring 2,3-DPG and ATP levels and, potentially, reduce formation of the breakdown products, hypoxanthine and uric acid. Guanosine, a purine nucleoside consisting of guanine linked by its N9 nitrogen to the C1 carbon of ribose, was chosen as the test nucleotide. Table 3 presents data obtained using a storage and/or rejuvenating composition including a 10 mM final concentration each of guanosine, sodium pyruvate, inorganic phosphate, and D-ribose.

TABLE 3

2,3-DPG and ATP of stored RBC in a guanosine containing solution

	Average 2,3-
Time Point	DPG	Range		% ATP
(Hours)	(μmol/ml)	(μmol/ml)	N =	increase

Control	0.25	N.A.	1
60 minutes	1.94	1.51-2.43	3	43
at 37° C.
60 minutes	0.51	0.28-0.83	3	32
at Room
Temperature

The 10 mM guanosine solution was capable of restoring 2,3-DPG levels when heated to 37° C. for 60 minutes. The concentrated guanosine composition was not completely soluble and, upon dilution, did not restore 2,3-DPG levels following room temperature incubation, although ATP levels were elevated.

Example 3

Table 4 presents data obtained using a storage and/or rejuvenating composition including 10 mM each of inorganic phosphate and D-ribose, and guanosine at the indicated concentration. The solutions did not include sodium pyruvate. Rejuvenation was observed for 60 minutes incubation at 37° C.

	TABLE 4

	2,3-DPG (μmol/ml)

	Control	0.20
	1 mM Guanosine	0.47
	5 mM Guanosine	1.30
	10 mM Guanosine	1.10

Example 4

Table 5 presents data obtained using a storage and/or rejuvenating composition including a final concentration of 10 mM each of L-arginine, inosine, D-ribose, sodium pyruvate, and inorganic phosphate. Rejuvenation was observed after 10 minutes and 60 minutes of incubation at 37° C.

	TABLE 5

	2,3-DPG (μmol/ml)

	Control	−0.17
	10 minutes at 37° C.	1.39
	60 minutes at 37° C.	4.25

Example 5

Rejuvenation was not observed for 60 minutes incubation at 37° C. when inosine was replaced with varying concentrations of inosine monophosphate in a storage and/or rejuvenating composition including 10 mM each of D-ribose, sodium pyruvate, and inorganic phosphate.

Example 6

Rejuvenation was not observed for 60 minutes incubation at 37° C. when inosine was replaced with varying concentrations of ribose-5-phosphate in a storage and/or rejuvenating composition including 10 mM each of D-ribose, sodium pyruvate, and inorganic phosphate.

Example 7

Rejuvenation was not observed for 10 minutes incubation at 4° C. in a storage and/or rejuvenating composition including 10 mM each of inosine, D-ribose, sodium pyruvate, and inorganic phosphate.
The complete disclosure of all patents, patent applications, and publications, and electronically available material (e.g., GenBank amino acid and nucleotide sequence submissions; and protein data bank (pdb) submissions) cited herein are incorporated by reference. The foregoing detailed description and examples have been given for clarity of understanding only. No unnecessary limitations are to be understood therefrom. The invention is not limited to the exact details shown and described, for variations obvious to one skilled in the art will be included within the invention defined by the claims.

Claims

1. A blood storage and/or rejuvenating composition comprising a nucleoside and D-ribose, with the proviso that the nucleoside is not inosine.

2. The composition of claim 1 wherein the nucleoside is selected from the group consisting of adenosine, deoxyadenosine, guanosine, deoxyguanosine, 5′-methyluridine, thymidine, uridine, deoxyuridine, cytidine, and deoxycytidine.

3. The composition of claim 1 wherein the nucleoside is guanosine.

4. The composition of claim 1 further comprising sodium pyruvate.

5. The composition of claim 1 further comprising an inorganic phosphate.

6. The composition of claim 1 wherein the composition is an aqueous solution.

7. A blood storage and/or rejuvenating composition comprising 75 to 1500 mM guanosine.

8. The composition of claim 7 further comprising D-ribose.

9. The composition of claim 8 wherein the concentration of the D-ribose is 75 to 1500 mM.

10. The composition of claim 7 further comprising sodium pyruvate.

11. The composition of claim 10 wherein the concentration of the sodium pyruvate is 75 to 1500 mM.

12. The composition of claim 7 further comprising an inorganic phosphate.

13. The composition of claim 12 wherein the concentration of the inorganic phosphate is 75 to 1500 mM.

14. The composition of claim 7 further comprising inosine.

15. The composition of claim 7 further comprising L-arginine.

16. The composition of claim 15 wherein the concentration of the L-arginine is 75 to 1500 mM.

17. A blood storage and/or rejuvenating composition comprising:

225 mM guanosine;

300 mM D-ribose;

300 mM sodium pyruvate; and

300 mM inorganic phosphate.

18. A method of storing blood, the method comprising contacting red blood cells with a blood storage and/or rejuvenating composition according to claim 1.

19. The method of claim 18 wherein the red blood cells are packed red blood cells or in whole blood.

20. A method of rejuvenating blood, the method comprising contacting red blood cells with a blood storage and/or rejuvenating composition according to claim 1.

21. The method of claim 20 wherein the red blood cells are packed red blood cells or in whole blood.

22. A method of rejuvenating blood, the method comprising:

providing red blood cells having a 2,3-diphosphoglycerate value lower than the value for freshly drawn blood; and

mixing the red blood cells with a blood storage and/or rejuvenating composition under conditions effective to increase the 2,3-diphosphoglycerate value,

wherein the blood storage and/or rejuvenating composition comprises guanosine.

23. The method of claim 22 wherein conditions effective comprise incubating the cells in the blood storage and/or rejuvenating composition at a temperature of 4° C. to 37° C.

24. The method of claim 23 wherein the temperature is room temperature.

25. The method of claim 22 wherein conditions effective comprise incubating the cells in the blood storage and/or rejuvenating composition for a time of at least 10 minutes.

26. The method of claim 25 wherein the time is 10 minutes to 48 hours.

27. The method of claim 26 wherein the time is 10 minutes to 4 hours.

28. The method of claim 27 wherein the time is 30 minutes to 2 hours.

29. The method of claim 22 wherein the blood storage and/or rejuvenating composition further comprises D-ribose.

30. The method of claim 22 wherein the red blood cells are packed red blood cells or in whole blood.

31. A method of rejuvenating blood, the method comprising:

providing red blood cells having an adenosine triphosphate value lower than the value for freshly drawn blood; and

mixing the red blood cells with a blood storage and/or rejuvenating composition under conditions effective to increase the adenosine triphosphate value,

wherein the blood storage and/or rejuvenating composition comprises guanosine.